Literature DB >> 9112600

Granulocyte-stimulating factor filgrastim and molgramostim induced recurring encephalopathy and focal status epilepticus.

O Kastrup, H C Diener.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9112600     DOI： 10.1007/s004150050086

Source DB:  PubMed          Journal:  J Neurol        ISSN： 0340-5354            Impact factor:   4.849


× No keyword cloud information.
  4 in total

1.  [No cross hypersensitivity between molgramostim and filgrastime: apropos of a case].

Authors:  R M Chichmanian; P Heudier; B Taillan; J G Fuzibet
Journal:  Therapie       Date:  1995 Sep-Oct       Impact factor: 2.070

2.  Adverse effects of molgramostim in marrow transplant recipients.

Authors:  C Ippoliti; D Przepiorka; T Smith; S Maiese; S Giralt; B S Andersson; A B Deisseroth; R E Champlin
Journal:  Clin Pharm       Date:  1993-07

3.  Multiple cerebral lesions complicating therapy with interleukin-2.

Authors:  B I Karp; J C Yang; M Khorsand; R Wood; T C Merigan
Journal:  Neurology       Date:  1996-08       Impact factor: 9.910

Review 4.  Neurologic complications of cytokine therapy.

Authors:  A D Forman
Journal:  Oncology (Williston Park)       Date:  1994-04       Impact factor: 2.990
  4 in total
  6 in total

1.  TNF-antagonist etanercept induced reversible posterior leukoencephalopathy syndrome.

Authors:  Oliver Kastrup; Hans Christoph Diener
Journal:  J Neurol       Date:  2008-02-20       Impact factor: 4.849

2.  Posterior reversible encephalopathy syndrome in cancer patients: a single institution retrospective study.

Authors:  Carlos Kamiya-Matsuoka; Asif M Paker; Linda Chi; Ayda Youssef; Sudhakar Tummala; Monica E Loghin
Journal:  J Neurooncol       Date:  2016-02-22       Impact factor: 4.130

3.  Primary brain tumors and posterior reversible encephalopathy syndrome.

Authors:  Carlos Kamiya-Matsuoka; David Cachia; Adriana Olar; Terri S Armstrong; Mark R Gilbert
Journal:  Neurooncol Pract       Date:  2014-09-14

4.  Risk factor analysis of posterior reversible encephalopathy syndrome after allogeneic hematopoietic SCT in children.

Authors:  D Zama; R Masetti; D M Cordelli; F Vendemini; L Giordano; G Milito; E Franzoni; F Porta; A Prete; R Rondelli; A Pession
Journal:  Bone Marrow Transplant       Date:  2014-08-18       Impact factor: 5.483

5.  Posterior reversible encephalopathy syndrome (PRES): electroencephalographic findings and seizure patterns.

Authors:  Oliver Kastrup; Markus Gerwig; Markus Frings; Hans-Christoph Diener
Journal:  J Neurol       Date:  2011-12-22       Impact factor: 4.849

6.  Posterior Reversible Encephalopathy Syndrome: The Spectrum of MR Imaging Patterns.

Authors:  O Kastrup; M Schlamann; C Moenninghoff; M Forsting; S Goericke
Journal:  Clin Neuroradiol       Date:  2014-02-20       Impact factor: 3.649
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.